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Abstract
Introduction
Patients with differentiated thyroid cancer (DTC) are treated with (near)-total thyroidectomy
followed by remnant ablation. Optimal radioiodine-131 (131I) uptake is achieved by withhold-
ing thyroid hormone (THW), pretreatment with recombinant human Thyrotropin Stimulating
Hormone (rhTSH) is an alternative. Six randomized trials have been published comparing
THW and rhTSH, however comparison is difficult because an uniform definition of ablation
success is lacking. Using a strict definition, we performed an observational study aiming to
determine the efficacy of rhTSH as preparation for remnant ablation.
Patients and Methods
Adult DTC patients with, tumor stage T1b to T3, Nx, N0 and N1, M0 were included in a pro-
spective multicenter observational study with a fully sequential design, using a stopping
rule. All patients received remnant ablation with 131I using rhTSH. Ablation success was de-
fined as no visible uptake in the original thyroid bed on a rhTSH stimulated 150 MBq 131I
whole body scan (WBS) 9 months after remnant ablation, or no visible uptake in the original
thyroid bed on a post therapeutic WBS when a second high dose was necessary.
PLOS ONE | DOI:10.1371/journal.pone.0120184 March 20, 2015 1 / 11
OPEN ACCESS
Citation: van der Horst-Schrivers ANA, Sluiter WJ,
Muller Kobold AC, Wolffenbuttel BHR, Plukker JTM,
Bisschop PH, et al. (2015) Recombinant TSH
Stimulated Remnant Ablation Therapy in Thyroid
Cancer: The Success Rate Depends on the Definition
of Ablation Success—An Observational Study. PLoS
ONE 10(3): e0120184. doi:10.1371/journal.
pone.0120184
Academic Editor: Peyman Björklund, Uppsala
University, SWEDEN
Received: September 9, 2014
Accepted: February 2, 2015
Published: March 20, 2015
Copyright: © 2015 van der Horst-Schrivers et al.
This is an open access article distributed under the
terms of the Creative Commons Attribution License,
which permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: This work was supported by the Genzyme
Corporation. The funders had no role in study design,
data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: On behalf of all authors, the
authors would like to state that this study received
funding from a commercial source the Genzyme
Results
After interim analysis of the first 8 patients, the failure rate was estimated to be 69% (90%
confidence interval (CI) 20-86%) and the inclusion of new patients had to be stopped. Final
analysis resulted in an ablation success in 11 out of 17 patients (65%, 95% CI 38-86%).
Conclusion
According to this study, the efficacy of rhTSH in the preparation of 131I ablation therapy is in-
ferior, when using a strict definition of ablation success. The current lack of agreement as to
the definition of successful remnant ablation, makes comparison between different ablation
strategies difficult. Our results point to the need for an international consensus on the defini-
tion of ablation success, not only in routine patient’s care but also for scientific reasons.
Trial Registration
Dutch Trial Registration NTR2395
Introduction
Patients with differentiated thyroid cancer (DTC) are initially treated with (near)-total thyroid-
ectomy followed in most cases by radioiodine-131 (131I) therapy (‘remnant ablation’) [1,2].
The aim of remnant ablation is to eliminate normal remnant thyroid tissue and to destroy
radioiodine-avid tumor cells; thus eliminating benign sources of thyroglobulin (Tg) and lower-
ing the rate of tumor recurrence. Optimal 131I uptake is achieved by withholding thyroid hor-
mone therapy (THW), a practice that induces hypothyroidism, leading to a diminished rate of
renal clearance of administered 131I and a prolonged Thyrotropin Stimulating Hormone (TSH)
stimulation [3]. With the introduction of recombinant human (rh)TSH, Thyrogen, Genzyme
Therapeutics), remnant ablation after pretreatment with rhTSH during euthyroidism has been
proposed as an alternative to THW. Using rhTSH avoids development of symptoms resulting
from hypothyroidism, maintains the quality of life and achieves a lower whole body radiation
as compared to preparation with THW [4,5].
Six randomized trials have been published comparing TWH and rhTSH stimulated rem-
nant ablation, with different success rates ranging between 70 and 94% (Table 1) [5–10]. Sever-
al of these studies, however, were underpowered because the primary endpoint was not
ablation success. The large difference in outcome between these studies can be explained by
several factors, such as the inclusion of patients from different risk categories, differences in the
extent of the primary surgery and the use of different definitions of ablation success [11].
Due to conflicting data regarding the possible benefits and drawbacks and the efficacy of
rhTSH stimulation on ablation success, we performed an observational study aiming to con-
firm the efficacy of the use of rhTSH as preparation for remnant ablation. We defined success-
ful ablation as no visible uptake on a subsequent whole body scan (WBS) [12]. The secondary
aim was to establish ablation success based on the additional Tg determination. We used an ob-
servational study design using continuous sequential analysis, as described earlier and for safe-
ty reasons we defined stopping rules of the occurrence of ablation failure [13].
rhTSH Stimulated Remnant Ablation Therapy in Thyroid Cancer
PLOS ONE | DOI:10.1371/journal.pone.0120184 March 20, 2015 2 / 11
Corporation: this money was used only to execute the
study and not for personal use of any of the authors.
This funding does not alter the authors' adherence to
PLOS ONE policies on sharing data and materials.
No further competing interests exists by any of the
authors which may have compromised the objectivity
or validity of the research, analyses, or interpretations
in the current manuscript.
Patients and Methods
Aim of the study
This was a prospective multicenter observational study with a fully sequential design (see statis-
tical analysis). The objective was to evaluate the success rate of 131I ablation therapy using
rhTSH stimulation. We considered a failure rate of 10% acceptable as compared to the failure
previously described in DTC patients after remnant ablation using THW [14–16].
The protocol for this trial and supporting CONSORT checklist are available as supporting
information; see S1 CONSORT Checklist and S1 Protocol.
Table 1. Performed randomized controlled trials comparing ablation success rates between recombinant human (rh)TSH and thyroid hormone
withdrawal.
Author Tumor
stages
N 131I
dose
Deﬁnition of
ablation
success
Evaluation
using
Success rates (%) Remarks
Based on WBS Based on Tg Based on WBS
(ultrasound) &
Tg
rhTSH
group
THW
group
rhTSH
group
THW
group
rhTSH
group
THW
group
Lee [6] T1, T2,
T3, N1a
291 1.1
GBq
No visible uptake
or < 0.1% on
WBS & normal
ultrasound and
Tg < 1.0 ng/mL
THW 91.3 94.4 92.8 91.0 3 groups; T4
THW, T3
THW &
rhTSH (T4
stopped for 4
days)
Schlumberger
[7]
T1/any
N &
T2N0
729 1.1
GBq
or 3.7
GBq
Normal
ultrasound &
Tg < 1 ng/mL, in
case of TgAb no
visible uptake
or  0.5% on
WBS
rhTSH ** ** 94.9 95.6 91.9 92.8 Tg < 1.0 ng/
mL (without
TgAb) at time
of ablation in
315 patients
Mallick [8] T1-T3/
any N
438 1.1
GBq
or 3.7
GBq
No visible uptake
or < 0.1% on
WBS and/ or
Tg < 2.0 ng/mL
rhTSH 93.8 93.8 87.6 86.2 87.1 86.7 Tg < 2.0 ng/
mL (without
TgAb) at time
of ablation in
110 patients
Pacini [9] T2-T4/
any N,
T0-T1/
N1*
63 3.7
GBq
No visible uptake
or < 0.1% on
WBS
rhTSH 100 75# 100
85.7#
83.3 85.7
Taieb [5] T1-T3/
any N
74 3.7
GBq
Not predeﬁned
Tg cut-off
level < 0.8 ng/mL
rhTSH 94 100 91.7 97.1 88.9
69.5#
97.1
88.6#
Chianelli [10] T1 (> 1
cm)/N0
24 2.0
GBq
Not predeﬁned
(no visible uptake
on WBS)
THW 90.5 95.2 85.0 90.0 75.0 90.0
* minimally invasive in case of T4
** WBS performed only in 23 patients
# Based on no visible uptake in the original thyroid bed on the WBS
WBS: Whole body scan, Tg: Thyroglobulin, THW: thyroid hormone withdrawal, rhTSH: recombinant human TSH.
doi:10.1371/journal.pone.0120184.t001
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In and exclusion criteria
Adult patients (18 years or older), who were diagnosed with histological proven DTC, low and
high risk (according the American Joint Committee on Cancer, 7th edition), with a TNM stage
of T1b (larger than 1cm), T2, T3, N0, N1 and M0 were eligible for inclusion. Exclusion criteria
were stage T4 disease and M1, known before ablation, as well as pregnancy. Since rhTSH can
lead to more severe side effects in patients with end stage renal disease we excluded patients
with an abnormal renal function defined by a serum creatinine> 130 μmol/L or a creatinine
clearance rate of less than 40 mL/min. Patients who had a major concurrent medical disease, a
previous history of a malignancy or had received an investigation with iodine-containing con-
trast agents within four months prior to the 131I ablation treatment were excluded. After De-
cember 2010 the inclusion of patients was permitted if the concurrent disease or prior
malignancy did not reduce survival expectation to less than one year. In case of recent (< four
months) exposure to iodine containing contrast agents the remnant ablation was postponed
for four months.
All patients provided informed written consent. The study was approved by the Medical Eth-
ics Review committee of all participating centers (University of Groningen, University Medical
Center Groningen (UMCG), Academic Medical Center (AMC), University of Amsterdam, Me-
ander Medical Center Amersfoort, Leiden University Medical Center, VU University Medical
Center). This trial was registered in the Dutch Trial Registration (number: NTR2395), at the 29th
of June 2010, due to logistic problems the first patient was already include 6 days prior to this
registration. The authors confirm that all ongoing and related trials for this drug are registered.
Study design
After (near)-total thyroidectomy and histological confirmation of DTC, thyroid hormone
treatment (Levothyroxine) was started at a dosage of 2 μg/kg bodyweight/day to reach a TSH
level< 0.3 mU/L. Three to six weeks after thyroidectomy, an ultrasound of the neck was per-
formed to confirm the absence of significant thyroid remnant tissue. Six weeks after surgery 0.9
mg rhTSH was administered by intramuscular injection on 2 consecutive days; 24 hours later
blood was withdrawn for measurement of Tg and Tg antibodies (Ab) and 3.7 GBq (100 mCi)
131I was administered. Patients underwent a 131I post therapeutic WBS 7 days later.
Six months after the remnant ablation the neck ultrasound was repeated. When suspicious
lymph nodes were encountered a fine needle aspiration (FNA) was performed. In case of a pos-
itive FNA, re-surgery was considered and patients were excluded from the analysis. Nine
months after the remnant ablation 0.9 mg rhTSH was administered intramuscularly on 2 con-
secutive days; one day later patients received 150 MBq (4 mCi) 131I. Serum TSH, Tg and TgAb
were measured, and a WBS was performed 3 days after the last rhTSH administration.
Patients with TgAb, and/or patients with a Tg< 1.0 ng/mL at the time of the remnant abla-
tion (despite visible uptake in the original thyroid bed on the post therapeutic WBS) were con-
sidered to have “unreliable” Tg results: undetectable Tg without measurable TgAb. These
patients, as well as those suspected of having distant metastases (visualized on the initial post
therapeutic WBS), received a second treatment, now with 5.55 GBq 131I after THW, 6 months
after the initial remnant ablation. [12,17,18]. All patient were on a low iodine diet for 1 week
prior to all 131I treatments.
In the individual participating centers all scans and laboratory results were evaluated in
order to make decisions as to treatment.
The primary and secondary endpoints were re-evaluated at the principal study center, the
UMCG. All WBS scans were reviewed by two independent nuclear physicians (AHB and BvE)
who were unaware of the outcome of the patients. There were no differences in their readings.
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Definition of ablation success
The primary definition of ablation success was: having no visible uptake in the original thyroid
bed on the rhTSH stimulated 150 MBq 131I WBS, or no visible uptake in the original thyroid
bed on the post therapeutic WBS when a second dose of 131I was administered. The second def-
inition of ablation success was: absence of visible uptake in the original thyroid bed combined
with a serum stimulated Tg level of< 1 ng/mL, when the Tg measurement was judged to
be reliable.
Thyroglobulin assay
Tg measurements were performed in the University Medical Center Groningen using a com-
mercial immunoradiometric assay (ThermoFischer, formerly Brahms Tg-Plus, Heningsdorf,
Germany). The Brahms Tg-Plus assay is calibrated against the CRM 457 standard. This assay
has an analytical sensitivity of 0.1 ng/mL and a functional sensitivity of 0.3 ng/mL (according
to Clinical and Laboratory Standards Institute (CLSI) EP5 guideline). The TgAb were also mea-
sured using a commercial radioimmuno assay (Brahms anti-Tg assay, Heningsdorf, Germany);
levels exceeding 46 U/mL were considered positive for the presence of Ab, reference value veri-
fication according to CLSI C28-A3 guideline.
Statistical analysis
Interim evaluation and stopping rules. This prospective study had a sequential design
with a stopping rule equipped with two boundaries, as described earlier by van der Zee et al
[13]. This analysis makes it possible to use every single consecutive remnant ablation in an in-
terim analysis. An ablation failure of 10% was considered to be acceptable based on the re-
ported literature [14–16].
Upper and lower boundaries were established on a true failure rate of 10% and its alternative
of 20%. The study was to be terminated after the crossing of either boundary. After passing the
upper boundary preparation with rhTSH would be concluded to be less effective than prepara-
tion using THW. After passing the lower boundary the failure rate of rhTSH stimulation
would be considered to be below 20% and thus acceptable. So, the preset upper boundary
would allow premature stopping in case of an observed failure rate in excess of the acceptable
rate of 10%. We calculated that a maximum total of 144 patients were needed (constant α =
0.014, cumulative α = 0.05; β = 0.10). This implied that with a true failure rate of 10%, the prob-
ability of passing the upper boundary would be below 5%. A preset lower boundary was made
(constant α = 0.2638; cumulative α = 0.05), allowing premature stopping of monitoring. Pas-
sage of that boundary would mean testing for futility, because with a true failure rate of 20%,
the probability of first passing this lower boundary, with subsequent passage of the upper
boundary, would be below 5%.
In case of passing the upper boundary, it was agreed in accordance with the Medical Ethics
Review committee that the study should be stopped prematurely because the use of rhTSH in
remnant ablation would be inferior in terms of ablation success.
Results
Patients
Between July 2010 and June 2011 a total of 50 patients were referred for remnant ablation after
(near)-total thyroidectomy because of a DTC in two (UMCG 48 patients, AMC 2 patients) of
the five participating centers. Eighteen patients (36.0%) were included in the study (Fig. 1,
Table 2). As rhTSH was not available in the Netherlands between February 2011 and December
rhTSH Stimulated Remnant Ablation Therapy in Thyroid Cancer
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2011 due to restricted supply, the study was not started in the other centers although approval
of the local Medical Ethic Review committees had been obtained. All patients except one (num-
ber 13) had no evidence of significant thyroid remnant tissue on the ultrasound, performed
three to six weeks after thyroidectomy. In patient number 13 there was a questionable small
remnant (< 9 mm). One patient with moderately reduced kidney function was included (num-
ber 7), one patient was excluded after 6 months from the final analysis as he was demonstrated
to have lymph node metastases and subsequently underwent an operation. The remaining pa-
tients did not have any suspected lymph nodes on the ultrasound. Urinary iodine concentra-
tion were< 100 μg/L, in 12 out of 15 patients (80.0%), with a median of 64 μg/L
(range< 39 μg/L—144 μg/L).
Interim analysis
In August 2011, the first 8 patients (numbers 1, 2, 3, 4, 5, 6, 7 and 9) were included in the
planned interim analysis which evaluated ablation success nine months after inclusion. In 4 pa-
tients (numbers 2, 3, 4 and 9) ablation was not successful, hence the upper boundary of the
stopping rule was passed. Accounting for the sequence of the events, the failure rate was
Fig 1. Flow chart of the inclusion of patients with differentiated thyroid carcinoma (DTC).
doi:10.1371/journal.pone.0120184.g001
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estimated to be 69% (90% confidence interval (CI) 20–86%). As a result remnant ablation
using rhTSH was concluded to be inferior to remnant ablation after THW. According to the
agreement with the Medical Ethics Review committee the inclusion of new patients had to be
stopped immediately.
Final analysis—ablation success
Ten out of 17 patients received a second high dose, 7 patients because of undetectable Tg without
measurable TgAb, 2 patients (numbers 10 and 15) had TgAb at the time of ablation, 103 U/mL
and 104 U/mL respectively. One patient (number 4) received a second high dose because of clini-
cal suspicion of multiple pulmonary metastases. Computed Tomography (CT) imaging per-
formed 1 month after the remnant ablation could not, however, verify these metastases and the
post therapeutic WBS after the second high dose also did not show these possible metastases.
Using the definition of no visible uptake on rhTSH stimulated 150 MBq 131I WBS or no visible
uptake in the original thyroid bed on a 131I post therapeutic WBS, the result was ablation success
in 11 out of 17 patients (65%, 95%CI 38–86%) (Table 2). Using the stricter definition of success-
ful ablation (no visible uptake in the original thyroid bed and a stimulated Tg level of< 1 ng/mL,
if reliable), the result was a successful ablation in 9 out of 17 patients (53%, 95% CI 28–78%).
Table 2. Baseline characteristics and thyroglobulin (Tg) levels at the time of the ablation, and results of evaluation of ablation success.
Characteristics at the time of 131I ablation therapy Results of Tg & WBS, 6 or 9 months after
remnant ablation, rhTSH stimulated (1) or
after a second high dose after THW (2)
N0 Age Gender Tumor Tg (ng/mL) Tg (ng/mL) Visible uptake on WBS
1 46 F PTC, T2N0 < 0.11 < 0.11 No (2)
2 65 F PTC, T3N0 < 0.11 0.13 Yes (2)#
3 71 M PTC, T2N0a 0.38 0.15 Yes (2)#
4 58 F PTC, T3N0 1.7 16 Yes (2)#
5 59 M PTC, T3N0 9.4 9.5 No (1)
6 52 M FTC, T3N0 6.3 < 0.11 No (1)
7 56 F PTC, T1aN0a 1.8 0.32 No (1)
8 43 M PTC, T3N0a 4.8 < 0.11 No (1)
9 29 F PTC, T2N0a 0.83 < 0.11 Yes (2)#
10 58 F FTC, T2N0 < 0.11* < 0.11 Yes (2)
11 26 F PTC, T2N0 < 0.11 < 0.11 No (2)
12 54 M PTC, T1bN0a < 0.11 < 0.11 No (2)
13 46 F FTC, T2N0b 3.6 < 0.11 No (1)
14 39 F PTC, T2N0a 8.7 11.0 No (1)
15 34 F PTC, T1bN0 0.14* < 0.11 Yes (2)
16 24 F PTC,T2N0 0.24 < 0.11 No (2)
17 77 F PTC, T1N0 3.0** < 0.11 No (1)
*TgAb positive,
**Measured at the Academic Medical Center (chemiluminescence immunoassay (LUMI-test Tg, BRAHMS, Berlin, Germany). Detection limit: 1 pmol/L.
Total assay variation: 7–13%).
amultifocality,
bincluding foci of PTC
F: female, M: male, PTC: papillary thyroid cancer, FTC: follicular thyroid cancer, Tg: Thyroglobulin, Ab: antibodies, WBS: whole body scan
#Patients 2,3,4 and 9 were not succesfully ablated in the interim analysis
doi:10.1371/journal.pone.0120184.t002
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Discussion
This study was performed to confirm the efficacy of 131I ablation therapy using rhTSH. Sur-
prisingly, our study had to be stopped as the evaluation of the first 8 patients demonstrated
that rhTSH stimulated remnant ablation with 3.7 GBq 131I was inferior to historical success
rates of remnant ablation using THW. Two recently published large randomized trials [7,8]
found no differences between THW and rhTSH, and a much higher ablation success rate
was observed.
It must be stressed that our observational study design with stopping rule differed from the
two randomized studies that used either a non-inferiority design [8] or an equivalence frame-
work [7]. However, other factors also contribute to the difference in outcome and these should
be discussed more in depth in order to expand the discussion on the indication of the use of
rhTSH.
In general, evaluation of ablation success is based on a surrogate endpoint instead of the
hard clinical endpoint of recurrence or mortality [19,20]. As shown in Table 1, the definition of
this surrogate endpoint differs among the published studies, and is also not consistent with cur-
rent guidelines [21–23]. There is no consensus regarding preference for THW or rhTSH during
the evaluation of ablative therapy, the cut-off value of Tg [24], the definition of a “negative”
WBS (no visible uptake or uptake< 0.5%) and the approach to patients with an undetectable
Tg without measurable TgAb at the time of ablation. Using a more strict definition; i.e THW
stimulated Tg< 1.0 ng/mL, no visible uptake on a WBS and a negative neck ultrasound, used
in the present study, will result in a lower ablation success rate. This is also illustrated in the
studies by Maenpaa et al. and Pacini et al, in which comparably low success rates of 52% and
54% were reported [25,26]. Using an even more strict cut-off level, feasible with the current Tg
assays, would have even led to lower success rate in our study. A stricter definition of ablation
success could bring to light the true difference between THW and rhTSH preparation.
It is unclear from the literature whether the finding of undetectable Tg in the absence of
TgAb is a proof of complete thyroidectomy, or is due to “unreliable” Tg and TgAb assays. Ac-
cording to our strict ablation protocol we prescribed a second high dose of 131I in the 7 patients
with an undetectable Tg without measurable TgAb at the time of ablation. We assumed that the
absence of Tg did not reflect a true complete thyroidectomy, but rather insufficient and “unreli-
able” Tg and TgAb assays. The fact that a remnant could be visualized in three out of seven pa-
tients partly confirms this assumption. This is in accordance with earlier results from our group,
in which we showed uptake in the original thyroid bed after THW in 95% of 94 patients, indicat-
ing the presence of remnant thyroid tissue despite undetectable Tg without TgAb [27]. However
some other explanations are possible. First, when surgery is performed by only a restricted num-
ber of experienced surgeons, then an undetectable Tg may correlate better with true total thy-
roidectomy, as might also be the case in other studies [6–8]. In our study the 18 patients
underwent surgery in nine different hospitals, which is still a common situation in the Nether-
lands and the majority of other countries. Second, the undetectable Tg without measurable
TgAb in the 4 remaining patients could also be the result of obtaining the Tg level one day after
the last rhTSH injection instead of three days, since previously it was shown that maximum
serum Tg levels are obtained three days after the final rhTSH injection [28]. Finally in rare cases
thyroid cancer cells express sodium/iodide symporter but are not able to produce Tg [29].
It has to be realized that the reduction of the recurrence rate after remnant ablation is proba-
bly the effect of the destruction of iodine sensitive tumor cells, and not of the normal remnant,
which is the subject of the definition of ablation success. Normal remnant thyroid tissue may
differ from that of tumor cells in that the latter have a reduced ability to take up iodine [30]. So,
one can hypothesize that tumor cells require a longer period of TSH stimulation of the
rhTSH Stimulated Remnant Ablation Therapy in Thyroid Cancer
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sodium-iodide symporter than normal thyroid cells. This suggests that THW can be expected
to be more effective for an adequate uptake of iodine by tumor cells. Because no prospective
studies are available comparing the effect of TWH and rhTSH stimulated ablation therapy
with hard clinical outcomes of recurrence or mortality, the long term outcome of the use of
rhTSH has not been proven to be safe on long term outcome. Still, in patients with low risk
DTC the disease free and overall survival rate is almost 100%. So the outcome in those low risk
patient groups is probably independent of the preablative strategy, and maybe even totally in-
dependent of the ablation therapy [2,31–34].
In conclusion, according to our study the efficacy of rhTSH in the preparation of 131I abla-
tion therapy is inferior if one uses a strict definition of ablation success and in daily practice.
Our data contribute to the debate on the role of rhTSH in the treatment of thyroid cancer pa-
tients. The lack of agreement as to the definition of successful remnant ablation must be added
to the list of variations in the management of thyroid cancer published recently by Haymart
et al. It is of utmost importance to agree on the definition of this endpoint, not only for the
sake of routine patient care but also for scientific reasons [35]. Efforts must be made to reach
an international consensus as to the definition of ablation success in order to make comparison
between different ablation strategies possible.
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